Chemoradiotherapy

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced cervical cancer, according to data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

The addition of pembrolizumab to concurrent chemoradiotherapy conferred a statistically significant and clinically meaningful increase in PFS among women with newly diagnosed high-risk locally advanced cervical cancer, topline data showed.

Primary transoral robotic surgery appeared associated with greater risk for short-term dysphagia compared with primary radiotherapy or chemoradiotherapy among patients with T1-T2 oropharyngeal squamous cell carcinoma, study results showed.

BMI in the overweight range appeared independently associated with favorable outcomes among patients who underwent chemoradiotherapy for nonmetastatic head and neck cancer, according to study results published in JAMA Network Open.

CHICAGO — Administering modified FOLFIRINOX chemotherapy before chemoradiation, surgery and adjuvant chemotherapy improved survival outcomes of patients with locally advanced rectal cancer, according to results of the PRODIGE 23 trial.

Chemoradiotherapy with a contact X-ray brachytherapy boost significantly increased clinical complete response and 3-year organ preservation rates in patients with early cT2-cT3 rectal adenocarcinoma, particularly tumors smaller than 3 cm.

NEW ORLEANS — Abhay Singh, MD, MPH, of the Cleveland Clinic discusses the results of a study presented here on therapy-related risk factors for the development of myelodysplastic syndrome and acute myeloid leukemia in cancer survivors.

The addition of pembrolizumab to chemoradiotherapy demonstrated a trend toward longer EFS among patients with locally advanced head and neck squamous cell carcinoma, according to data presented at ESMO Congress.

CHICAGO — A sequential schedule of fixed-dose pembrolizumab with chemoradiotherapy conferred numerically higher PFS rates vs. concurrent timing of the drug among patients with locally advanced head and neck cancer, study results showed.

Neoadjuvant gemcitabine-based chemoradiotherapy prolonged OS compared with upfront surgery among patients with resectable and borderline resectable pancreatic cancer, according to phase 3 study results in Journal of Clinical Oncology.